Menu
AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.

AbbVie, AstraZeneca Challenge Kansas’ New Contract Pharmacy Access Law

Shannon Young, Associate Editor/Senior Writer Views
Two major drug manufacturers this week sued Kansas in an effort to block the state’s new contract pharmacy access law, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live